Ocuphire Pharma Management
Management criteria checks 1/4
Ocuphire Pharma's CEO is George Magrath, appointed in Nov 2023, has a tenure of less than a year. directly owns 0.1% of the company’s shares, worth $40.89K. The average tenure of the management team and the board of directors is 0.5 years and 3.5 years respectively.
Key information
George Magrath
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | 0.1% |
Management average tenure | less than a year |
Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Ocuphire drops 11% on $15M at-the money direct offering
Jun 04Ocuphire Pharma EPS beats by $0.36
May 07Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?
Feb 08Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Jan 06Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Jan 05CEO
George Magrath (39 yo)
less than a year
Tenure
Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Ocuphire Pharma, Inc. since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sect...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | no data | US$91.53k | 0.46% $ 184.9k | |
Senior Vice President of Corporate Development & Secretary | no data | US$446.50k | 0.43% $ 176.2k | |
Senior Vice President of Finance | no data | US$499.27k | 0.031% $ 12.6k | |
CEO & Director | less than a year | no data | 0.10% $ 40.9k | |
Chief Financial Officer | less than a year | no data | 0.60% $ 245.4k | |
Chief Operating Officer | less than a year | no data | 0.0081% $ 3.3k | |
Chief Scientific & Development Officer | less than a year | no data | no data | |
Head of Market Development & Commercialization | 2.3yrs | no data | no data |
0.5yrs
Average Tenure
45yo
Average Age
Experienced Management: OCUP's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | 3.5yrs | US$91.53k | 0.46% $ 184.9k | |
CEO & Director | less than a year | no data | 0.10% $ 40.9k | |
Independent Director | 3.5yrs | US$85.78k | 0.32% $ 130.7k | |
Chief Medical Advisor | 6.3yrs | US$69.53k | 0.25% $ 100.3k | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | 4.3yrs | no data | no data | |
Independent Chairman | 3.5yrs | US$117.03k | 0.10% $ 40.8k | |
Member of Medical Advisory Board | no data | no data | no data | |
Lead Independent Director | 3.5yrs | US$105.78k | 0.15% $ 59.3k | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data |
3.5yrs
Average Tenure
56yo
Average Age
Experienced Board: OCUP's board of directors are considered experienced (3.5 years average tenure).